Indications : התוויות

4.1    Therapeutic indications

Chronic hepatitis B
Pegasys is indicated for the treatment of both HBeAg-positive and HBeAg-negative chronic hepatitis B in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.



Page 1 of 1           Pegasys PFS and PFP_PI_Ver 1.0
Based on EMEA/H/C/000395/IB/82_09 2015
PEGASYS                                                      MoH Approved Prescribing Information Pre-Filled Syringe, Pre-Filled Pen 135 & 180 mcg                                 December 2015 Chronic hepatitis C:
Pegasys is indicated for the treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA, including patients with compensated cirrhosis and/or co-infected with clinically stable HIV (see section 4.4).

The optimal way to use Pegasys in patients with chronic hepatitis C is in combination with ribavirin. The combination of Pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin.

Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.